Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy in Patients With EGFR-mutant Resectable NSCLC : A Prospective, Multicenter, Single Arm, Phase II Exploratory Clinical Study

NCT07807722 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT07807722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy in Patients With EGFR-mutant Resectable NSCLC : A Prospective, Multicenter, Single Arm, Phase II Exploratory Clinical Study
Lead sponsor
Hubei Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 21, 2026
Completion date
September 30, 2030
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, neoadjuvant therapy, nsclc (non-small cell lung cancer)